To Book an Appointment

Mounjaro (Tirzepatide): Its Uses in Diabetes and Obesity

By Dr. Ambrish Mithal in Endocrinology & Diabetes

Nov 20 , 2025 | 2 min read

Mounjaro is primarily an anti-diabetic medication and is highly effective in people with type 2 diabetes, even those with a BMI of 27. It not only helps improve insulin secretion and control blood glucose levels but also significantly aids in weight loss. Additionally, GLP-1 receptor agonists, such as Mounjaro, protect vital organs, including the heart, liver, and kidneys. In summary, the key benefits of diabetes management are:

Better control of blood glucose.
Significant weight reduction.
Reduction in long-term complications of diabetes.

Use in People Who Are Obese Without Diabetes

Mounjaro is also approved for the treatment of obesity, regardless of diabetes status. Obesity itself is a serious health condition that can lead to premature heart disease, diabetes, hypertension, fatty liver, and an increased risk of certain cancers. Therefore, individuals with a BMI over 30 are eligible for treatment with Mounjaro, provided lifestyle interventions alone have not been effective.

It is important to note that using Mounjaro in people without diabetes is not a cosmetic treatment; it is a medical intervention for a health condition. Other GLP-1 drugs, such as Tirzepatide, Semaglutide, and Vikovi, have also shown significant benefits in managing obesity.

Clinical Considerations

Mounjaro is a potent anti-diabetic drug that causes substantial reductions in blood glucose (HbA1c), body weight, and diabetes-related complications. It is increasingly being used as a first-line therapy for diabetes. The only current limitations are:

Cost: It remains expensive and is not widely accessible.
Route of administration: It is injectable, which may be a barrier for some patients.

Future developments may include oral formulations of GLP-1 drugs that are equally effective and more affordable.

Patient Requests and Guidelines

Many patients request these drugs after hearing about them in the media or through social contacts. However, as physicians, it is crucial to prescribe these medications only when medically indicated, not to satisfy cosmetic or non-medical desires. Appropriate candidates include:

Overweight or obese individuals with a BMI over 30 who have not responded to lifestyle measures.
People with type 2 diabetes who are overweight, poorly controlled, and at risk of complications.

While some patients may be apprehensive about potential side effects, proper guidance ensures the safe and effective use of medications.

Administration Preferences

Worldwide, pen devices are preferred over vials for injectable treatments, as they are easier to use and require no assistance. When generic versions of other GLP-1 drugs become available, some patients may switch to reduce costs. However, since Mounjaro is a distinct molecule, it is unclear how the market will respond.

Conclusion

Mounjaro is highly effective for both diabetes and obesity, offering multiple health benefits beyond glucose control, and is suitable for patients following clinical guidelines.

Written and Verified by: